Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
We rose to circa 140 on this yesterday morning before wider market sentiment took us back down. It shouldn’t have. This is further proof of concept (though pre clinical) and shows how far AVA6000 will go in proving the entire platform.
Now all that nonsense is done with…..
Back to this
https://t.co/wRVH14hQyt
Than to tweet on Twatter and prove it.
Orca stocks tweet 23rd of feb….
https://mobile.twitter.com/OrcaStocks/status/1628673604803039232
Orca stocks tonight (or quint or whatever the fck)
https://mobile.twitter.com/OrcaStocks/status/1636140245069492229
I mean. No? No he wasn’t right. And that’s why I can’t stand traders by and large because they’re full of ****.
Hey Siri.
Please calculate a £200mn (may as well play the make **** up game) license deal for 3996 with a 10% royalty meaning no dilution, 100% market share at $5bn at an 8.9 multiple….. Siri…… SIRI?! Are you snoring?
Sorry it’s fallen asleep through boredom.
Oh well. Eh, did anyone see the poster today? 3996 Looks remarkably consistent doesn’t it!
So even with 100% market share, since whoever would possibly buy us would take us on future earnings, a market of $5bn dollars per annum, and a license deal for 3996 to fund us through clinic so no dilution, you still can’t get to 371? Or are we not including take overs? I’ve forgotten the rules. It’s about 60000 posts ago and I don’t want the carpel tunnel syndrome that would come with scrolling back that much.
“A drug approved for Phase I clinical trials has a 10.4% likelihood of eventually reaching FDA approval. If the drug moves to Phase II trials, the likelihood of approval rises to 16.2%”
What if the drug is actually a delivery mechanism for a decades old form of chemo with a very well known awful safety profile, which has been in clinic now for (ages…. I can’t remember exactly how long) and shows a massively improved safety profile? Then what’s the chance of success? Much higher doses being delivered, the trial hasn’t been stopped, MTD to blow standard dosing for dox out of the water. Can you add those calculations in please? And can you also assume the market will increase in size to say 3bn to be conservative and also add in AVA3996 showing a similar profile, pre clinic, (dogs not needing dosing breaks mid clinic vs needing them etc) the 10% chance you allocated above since that’ll be clinical pretty soon too and I believe that market is circa $2bn per annum. Thanks.
Wow. That’s amazing. So you’ve had to pump more and more money in to Harl after your genius sale at a quid where you could have sold at 180 like the genius you aren’t.
He1 was 28p when you lost out. Fail.
ADV and SNG have never recovered. Fail.
You lost. That money is gone. It’s cost you a lot more to try and scramble losses back. Fail.
It’s not small minded. But as you warned the board weeks ago, I’m warning newbies as you call them that you are the absolute king of failures on LSE. Fail.
Shouldn’t you be warning everyone on the Harl board that it’s dropped another 5%. You’re heading towards another 50% loss over there Wyndrone. 2.5p to go and it’s going from the looks of things.
So…. 60% He1.
90% SNG
95% ADV.
soon to be 50% Harl after selling Avacta for a quid.
And you feel well positioned to dish out trading advice here. Amazing.